Based on the Office for National Statistics population and the NHS Quality and Outcomes framework 2023-24 around 614,000 adults in England have heart failure. Of these, around 63% (387,000) adults are ...

Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS. These ...

There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

The lives of thousands of people with chronic kidney disease could be changed for the better after NICE today (Friday, 23 May) recommended a new treatment option for use in the NHS. Just over 4,200 ...

Marstacimab is the first under the skin (subcutaneous) injection for severe haemophilia B and today’s decision comes just weeks after the treatment received its UK licence. Given as a once-weekly ...

There is a simple discount patient access scheme for capivasertib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Modular updates are a new way to make smaller, more frequent subject-specific updates to the methods and processes we follow when evaluating health technologies and developing guidelines. We launched ...

Our draft guidance does not, at present, recommend the treatment’s use for future patients with this rare, life limiting disease due to its high price and the limited evidence of long-term ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Dostarlimab (Jemperli) with platinum-based chemotherapy is available on the NHS. It is a possible treatment for when systemic treatment is suitable in adults with primary endometrial cancer that has ...

Dostarlimab (Jemperli, GlaxoSmithKline) is indicated 'in combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and ...